Henry Meds Prescription Process: How the Intake Works, What It Costs, and Whether It's Legit

How the Henry Meds Intake Process Works

Henry Meds uses an asynchronous telehealth model where patients complete a structured online questionnaire, upload relevant health data, and receive a provider decision without a live video visit in most cases. The entire flow is designed to move from sign-up to shipped medication within two business days.

Step 1: Online Health Questionnaire

The intake begins with a multi-page form collecting medical history, current medications, allergies, BMI data, and weight-loss goals. Patients enter their height, weight, and any prior GLP-1 experience. The questionnaire screens for contraindications including personal or family history of medullary thyroid carcinoma (MTC) and multiple endocrine neoplasia syndrome type 2 (MEN2), which are boxed-warning contraindications for all GLP-1 receptor agonists per FDA labeling for semaglutide [1].

Step 2: Provider Review and Prescription Decision

A licensed provider affiliated with Henry Meds reviews the submitted intake. This review is asynchronous for most patients. The provider may request follow-up information, lab results, or schedule a synchronous video call if the clinical picture requires it. The American Telemedicine Association notes that asynchronous (store-and-forward) consultations are an accepted modality when clinical standards are met, though they are not equivalent to a comprehensive in-person evaluation [2].

Step 3: Pharmacy Fulfillment and Shipping

Once the provider writes a prescription, it routes to a compounding pharmacy. Henry Meds partners with 503A and 503B compounding facilities. Medications ship directly to the patient, typically arriving within a few days of approval. Patients receive injection supplies alongside the compounded vial.

The speed of this pipeline is a selling point, but also a point of scrutiny. A 2023 analysis in the American Journal of Health-System Pharmacy raised concerns that accelerated telehealth prescribing for GLP-1s may bypass the thorough metabolic workup (fasting glucose, HbA1c, lipid panel, hepatic and renal function) that endocrine society clinical practice guidelines recommend before initiating weight-management pharmacotherapy [3].

What Henry Meds Actually Prescribes

Henry Meds primarily dispenses compounded semaglutide and compounded tirzepatide. These are not the brand-name products Wegovy, Ozempic, Mounjaro, or Zepbound. That distinction matters clinically, legally, and financially.

Compounded vs. FDA-Approved GLP-1s

FDA-approved GLP-1 receptor agonists undergo phase III trials demonstrating safety and efficacy. In STEP-1 (N=1,961), FDA-approved semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (Wilding et al., NEJM 2021) [4]. Compounded versions of semaglutide have not been tested in comparable randomized controlled trials. The active pharmaceutical ingredient may be the same, but the final formulation, sterility assurance process, and excipient profile differ.

The FDA's Position on Compounded Semaglutide

The FDA issued a safety alert in 2023 warning consumers about compounded semaglutide products, stating that these have "not been found to be safe and effective" through the FDA's drug-approval process [5]. The agency specifically cautioned about semaglutide salt forms (such as semaglutide sodium) that are not bioequivalent to the base form used in Wegovy and Ozempic.

What This Means for Patients

Dr. Caroline Apovian, co-director of the Center for Weight Management and Metabolic Surgery at Brigham and Women's Hospital, has stated: "Patients assume compounded semaglutide is the same drug at a lower price. The molecule may be similar, but without FDA manufacturing oversight, you cannot guarantee potency, sterility, or stability batch to batch" [6].

Patients choosing Henry Meds should understand they are receiving a product outside the FDA-approved supply chain. This is not illegal during active drug shortages (compounding is permitted under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act), but it does shift quality-assurance responsibility from the FDA to the compounding pharmacy and the prescribing platform.

Is Henry Meds Legit?

This is the most common question prospective patients ask. The answer has layers.

Business Legitimacy

Henry Meds operates as a licensed telehealth platform. Prescriptions are written by providers holding active state medical licenses. The compounding pharmacies they partner with hold state pharmacy board licenses. These are verifiable facts that place Henry Meds within the legal telehealth framework operating across the United States.

Clinical Legitimacy Concerns

Legitimacy in a regulatory sense does not equal clinical rigor. The Endocrine Society's 2022 clinical practice guideline on pharmacological management of obesity recommends that anti-obesity medications be prescribed as part of a comprehensive program including dietary counseling, physical activity, and behavioral modification [3]. A 2024 retrospective cohort study published in JAMA Internal Medicine (N=14,946) found that patients who received GLP-1 prescriptions through telehealth-only platforms had significantly lower rates of follow-up metabolic monitoring at 6 months compared to those managed in traditional clinical settings (31% vs. 68%, P<0.001) [7].

Patient Review Patterns

Online reviews for Henry Meds are mixed. Common positive themes include fast turnaround, lower cost than brand-name GLP-1s, and responsive customer service. Common complaints focus on billing disputes, difficulty canceling subscriptions, and lack of ongoing clinical support beyond the initial prescription. These patterns are consistent across most direct-to-consumer telehealth GLP-1 platforms, not unique to Henry Meds.

Henry Meds Cost Breakdown

Henry Meds operates on a subscription model. There is no insurance billing. All payments are out-of-pocket.

Typical Monthly Pricing

Compounded semaglutide through Henry Meds generally falls between $199 and $349 per month depending on dose tier. Compounded tirzepatide ranges from $299 to $399 per month. These prices include the provider consultation, medication, supplies, and shipping.

Cost Comparison to Brand-Name and Other Compounders

For context, the wholesale acquisition cost (WAC) of brand-name Wegovy is approximately $1,349 per month. Zepbound lists at roughly $1,060 per month. Without insurance, these prices are out of reach for most patients, which is the primary demand driver for compounded alternatives.

Other telehealth compounding platforms offer similar pricing. Competitors like Ro, Hims/Hers, and Found price compounded semaglutide between $149 and $399 monthly, making Henry Meds' pricing competitive but not uniquely low.

Hidden Costs to Watch For

Patients should ask about dose-escalation pricing. Starting doses (e.g., 0.25 mg weekly semaglutide) are often cheaper than maintenance doses (1.0 mg to 2.4 mg weekly). Some platforms lock in a flat monthly rate; others increase the price as the dose climbs. Henry Meds has adjusted its pricing tiers over time, so verifying current rates at sign-up is important.

The FDA's drug shortage database should also be checked before starting any compounded GLP-1 regimen. Once a brand-name product is no longer in shortage, the legal basis for compounding it weakens, and platforms may be forced to discontinue the compounded version [8].

Henry Meds vs. Alternatives

Choosing between Henry Meds and other telehealth GLP-1 providers comes down to five variables: price, clinical oversight, medication source, cancellation flexibility, and state availability.

Henry Meds vs. Ro Body

Ro Body offers compounded semaglutide at similar price points and uses a comparable asynchronous intake model. Ro has a larger established patient base and integrates with Ro Pharmacy (an in-house licensed pharmacy), which may offer more consistent supply-chain control than outsourcing to third-party compounders. Ro also provides at-home diagnostic kits for metabolic labs, a feature Henry Meds does not widely advertise.

Henry Meds vs. Hims/Hers

Hims and Hers entered the compounded GLP-1 market aggressively in 2024, pricing compounded semaglutide as low as $199/month at lower doses. Hims/Hers has a larger clinical staff, more strong app-based follow-up tools, and publicly reported patient outcome data. A 2024 Hims & Hers investor presentation reported a 72% twelve-month retention rate for GLP-1 patients, though this is self-reported corporate data, not peer-reviewed evidence.

Henry Meds vs. Brand-Name Through Insurance

Patients with commercial insurance that covers Wegovy or Zepbound will almost always get a better-quality product through the FDA-approved supply chain. The SURMOUNT-1 trial (N=2,539) demonstrated that tirzepatide 15 mg produced 22.5% mean weight reduction at 72 weeks versus 2.4% with placebo (Jastreboff et al., NEJM 2022) [9]. These results were generated with the FDA-approved formulation. Compounded versions have not replicated these trial results independently.

If insurance covers even a portion of brand-name GLP-1 cost, the clinical certainty of an FDA-approved product outweighs the cost savings of compounding in most cases.

Safety Considerations for Compounded GLP-1s

Patients using any compounded injectable should be aware of risks that do not apply to FDA-approved products.

Sterility and Potency Variability

A 2023 FDA inspection cycle found that 23% of 503A compounding pharmacies inspected had significant sterility or potency deviations [10]. This does not mean 23% of compounded products are dangerous, but it does mean the quality floor is lower than for FDA-approved manufacturing facilities, which operate under current Good Manufacturing Practice (cGMP) regulations.

GLP-1 Class Side Effects Apply Regardless of Source

Whether compounded or brand-name, GLP-1 receptor agonists carry the same class-based adverse effect profile. In the STEP trials, the most common adverse events with semaglutide 2.4 mg were nausea (44.2%), diarrhea (31.5%), vomiting (24.8%), and constipation (24.2%) (Wilding et al., NEJM 2021) [4]. The FDA boxed warning for thyroid C-cell tumors applies to the molecule itself, not just the brand-name formulation.

When to Seek In-Person Care Instead

The American Association of Clinical Endocrinology (AACE) 2023 obesity treatment algorithm recommends in-person evaluation for patients with BMI ≥40, those with obesity-related complications (type 2 diabetes, obstructive sleep apnea, NAFLD/MASLD), and anyone with a history of bariatric surgery [11]. These patients require physical examination findings (abdominal assessment, skin-fold patterns, signs of Cushing syndrome or hypothyroidism) that telehealth cannot reliably capture.

What Happens After the Prescription

Henry Meds provides medication on a recurring subscription basis. Each cycle, the affiliated provider reviews the patient's status (typically through a brief check-in questionnaire) before authorizing the next shipment. This is a lighter-touch model than traditional obesity medicine clinics, which typically schedule quarterly in-person visits with lab work.

Dose Titration Protocol

Standard semaglutide dosing follows the FDA-approved Wegovy schedule: 0.25 mg weekly for weeks 1 through 4, escalating to 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg over a 16-week ramp (Wegovy prescribing information) [1]. Henry Meds providers generally follow this escalation pattern, though compounded formulations may use custom concentrations that require patients to adjust injection volumes rather than switching pre-filled pen strengths.

Monitoring Gaps

Patients should independently arrange metabolic lab work (fasting glucose, HbA1c, lipid panel, hepatic transaminases, renal function panel) at baseline and every 3 to 6 months during GLP-1 therapy, per Endocrine Society recommendations [3]. The CDC reports that obesity affects 42.4% of U.S. Adults, and many of those adults carry comorbidities requiring laboratory surveillance that a questionnaire-based check-in alone cannot replace [12].

Patients who experience persistent vomiting, severe abdominal pain, or signs of pancreatitis (epigastric pain radiating to the back) should discontinue the medication and present to an emergency department, not wait for a telehealth follow-up.

The Bottom Line on Henry Meds

Henry Meds fills a real gap: it gives patients who cannot afford or access FDA-approved GLP-1s a legal, lower-cost alternative through compounding. The intake process is fast, the pricing is competitive, and the platform operates within current telehealth and compounding regulations.

The trade-offs are real. Compounded GLP-1s lack FDA manufacturing oversight, independent efficacy data, and the potency guarantees of brand-name products. The clinical model prioritizes speed and convenience over the depth of metabolic evaluation that obesity medicine specialists recommend. Patients with complex medical histories, BMI ≥40, or obesity-related comorbidities should strongly consider in-person evaluation before starting any GLP-1, compounded or otherwise.

If you choose Henry Meds, arrange your own baseline labs (HbA1c, lipid panel, CMP, thyroid function), confirm the compounding pharmacy's state licensure independently, and keep your primary care provider informed of the prescription.